Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Barclays Global Healthcare Conference

Merck to Present at the Barclays Global Healthcare Conference

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021

Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021

Johnson & Johnson

Johnson & Johnson CEO Alex Gorsky discussed on Tuesday the company's unprecedented partnership with rival Merck to boost production of its Covid-19 vaccine.

Johnson & Johnson CEO on Merck vaccine partnership: 'Extraordinary times take extraordinary efforts'

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck with Funding to Expand Merck's Manufacturing Capacity

Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck's Manufacturing Capacity for COVID-19 Vaccines and Medicines

Merck will help rival drugmaker Johnson & Johnson produce its single-dose coronavirus vaccine, the White House said Tuesday. The two pharmaceutical giants have reached a “historic manufacturing partnership” to ramp up J&J's supply of its COVID-19 shot, which the feds cleared for emergency use on Saturday, White House Press Secretary Jen Psaki said.

Merck to help Johnson & Johnson produce COVID vaccine

Merck will reportedly step in to help Johnson & Johnson manufacture its coronavirus vaccine in a deal that binds two rival vaccine stocks. J&J is reportedly behind in production.

Merck, J&J Reportedly Forge Covid Vaccine Alliance — Here's What You Need To Know

The United States is using the Defense Production Act to equip drugmaker Merck & Co's plants to make Johnson & Johnson's just approved COVID-19 vaccine, White House press secretary Jen Psaki said on Tuesday.

White House using Defense Production Act to equip Merck plants for Johnson & Johnson vaccine

Two of the country's largest pharma companies will partner to speed up COVID-19 vaccine production. President Joe Biden will announce a partnership between Merck and Johnson & Johnson, senior administration officials told The Washington Post.

Merck will reportedly help produce Johnson & Johnson COVID-19 vaccine shots after failing to make its own (MRK, JNJ)

The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.

Coronavirus Update: U.S. COVID vaccine supply to be boosted by Merck helping make J&J vaccine

Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, a White House official said.

Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official

U.S. President Joe Biden will announce that Merck & Co (NYSE: MRK) will help manufacture its rival Johnson & Johnson's (NYSE: JNJ) newly authorized coronavirus vaccine to boost the supply, Washington Post reports. The officials started looking for additional manufacturing capacity amid concerns about Johnson & Johnson's production delays.

Merck To Offer Hand With JNJ COVID-19 Vaccine Production, Biden Administration Says: Report

President Joe Biden announced Tuesday that pharmaceutical giant Merck will help make Johnson & Johnson's Covid-19 vaccine.

Biden to announce Merck will help make Johnson & Johnson's Covid vaccine

Biden reportedly set to announce Merck assistance in J&J vaccine manufacturing

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide

Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide

New funds, new partners: Seattle's Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics.

Presage Biosciences raises $13M and inks new deal with Merck for cancer drug tests

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pandion Therapeutics, Inc. (NasdaqGS: PAND) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Pandion will receive only $60.00 in cash for each share of Pandion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or

PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US

Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US

Automatic Data Processing

Blackrock Inc

Home Depot

Coca-Cola

PepsiCo

UnitedHealth Group

In this article series, we provide a summary of upcoming ex-dividend dates. A summary table provides relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: March 2-12, 2021

The FDA has accepted Merck & Co Inc's (NYSE: MRK) marketing application seeking approval for gefapixant, for review. The selective P2X3 receptor antagonist is being developed to treat refractory chronic cough or unexplained chronic cough in adults.

Merck's Cough Drug Gefapixant Application Accepted For US Review

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.

Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review

U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review

DARMSTADT, Germany, March 1, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a worldwide in-licensing agreement with Debiopharm, Lausanne, Switzerland, for the development and commercialization of xevinapant (Debio 1143)....

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant

Bank of New York Mellon

Kraft Heinz

SPDR S&P 500 ETF Trust

Hillman Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Hillman Capital's Top 4 Buys of the 4th Quarter

Merck & Co Inc (NYSE: MRK) had reported a significant snag in its latest annual filing (10K), wherein the company has received feedback from the FDA regarding its COVID-19 drug, MK-7110. The agency has asked for additional data beyond the study conducted by OncoImmune to support a potential emergency use application.

FDA Requires Additional Data On Merck COVID-19 Drug, EUA Moved Back

Is Merck stock a buy as the company plans to buy Pandion Therapeutics, an early-stage biotech testing drugs for autoimmune diseases? Check out Merck stock chart and materials.

News for Merck Stock (MRK)